Long-term efficacy of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndrome
In light of the pivotal role of IL-1β and IL-18 in sJIA, MAS and interstitial lung disease, MAS825 might represent a possible valid and safe option in the treatment of drug-resistant sJIA, especially in the presence of high serum IL-18 levels.
Authors
- Silvia Rosina (ORCID: https://orcid.org/0000-0002-3667-6155)
- Alessandro Consolaro (ORCID: https://orcid.org/0000-0002-0065-7614)
- Arinna Bertoni (ORCID: https://orcid.org/0000-0001-8317-9584)
- Clara Malattia (ORCID: https://orcid.org/0000-0002-0521-9488)
- Anna Corcione (ORCID: https://orcid.org/0000-0003-2439-1221)
- Roberta Caorsi (ORCID: https://orcid.org/0000-0003-0131-7846)
- Caterina Matucci‐Cerinic (ORCID: https://orcid.org/0000-0003-3710-0569)
- Stefano Volpi (ORCID: https://orcid.org/0000-0002-7129-868X)
- Marco Gattorno (ORCID: https://orcid.org/0000-0003-0704-1916)
- Federica Penco (ORCID: https://orcid.org/0000-0002-8437-3466)
- Valentina Natoli (ORCID: https://orcid.org/0000-0001-6733-4134)
- Serena Palmeri (ORCID: https://orcid.org/0000-0001-7670-6825)
- Riccardo Papa (ORCID: https://orcid.org/0000-0002-9626-5470)
- Stefania Viola (ORCID: https://orcid.org/0000-0003-0773-8158)
- Angelo Ravelli
Institutions
- Istituto Giannina Gaslini (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1093/rheumatology/keae440
- Citations
- 12
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- Eli Lilly and Company
- Pfizer
- Alexion Pharmaceuticals
- Swedish Orphan Biovitrum